(June 29, 2011, New York, NY) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of various prescription drugs, is concerned that the recent Supreme Court decision limiting the liability of generic drug manufacturers will have significant consequences. On June 23, the Supreme Court of the United States issued [...]
An off-label use of Topamax could put patients at risk for increased suicidal tendencies and cause adverse effects on unborn babies, according to a Drug Safety Communication issued by the Food and Drug Administration (FDA) on March 4. Topamax has already been used to treat alcohol dependency, eating disorders and migraines, but a new study [...]
(New York, NY, June 6, 2011) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, urges those individuals who have taken Fosamax to consult their physicians to determine their risk for femur fractures, even despite recent suggestions that potential risks are less than previously thought. [...]
(New York, NY, May 31, 2011) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is pleased by the consolidation of federal Fosamax cases for purposes of pre-trial procedures. By order dated May 23, 2011, the United States Panel on Multidistrict Litigation in case number [...]
(August 19, 2011) A Fosamax lawsuit was filed by plaintiffs claiming that they are at a higher risk of developing osteonecrosis (ONJ) because they use Fosamax. Attempts to file a three-state lawsuit against the product were rejected by Judge John F. Keenan of the United States District Court for the Southern District of New York. [...]
